Barely Significant
← all excerpts

Efficacy and safety of IL-23 p19 inhibitors in the treatment for inflammatory bowel disease: a systematic review and meta-analysis.

Front Pharmacol · 2025 · PMC12066446 · PMID 40356994

Europe PMCDOI
1
hedged sentence
0.3900
closest p · 7.8× alpha
0.3900
boldest claim

The sentences

a decreasing trendp = 0.39not close (p > 0.1)
However, the incidence of serious infection showed a decreasing trend (CD: RR 0.28, 95% CI 0.13–0.61; I 2 = 0%, p = 0.39; UC: RR 0.56, 95% CI 0.18–1.69; I 2 = 9%, p = 0.33; Supplementary Figure S5 ). 3.6.2 Maintenance therapy According to maintenance trial results, treatment of IBD patients with an IL-23 p19 inhibitor showed no connection with the significantly greater AEs compared with placebo (CD: RR 1.00, 95% CI 0.89–1.13; I 2 = 29%, p = 0.25; UC: RR 0.96, 95% CI 0.87–1.06; I 2 = 0%, p = 0.44; Supplementary Figure S6 ), but the results were not statistically significant.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.